Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Hankerchiefon Aug 17, 2020 10:43am

160 Views

Post# 31417439

RE:RE:This is good!

robertshaw wrote:

Hankerchief wrote:
The Company is planning to commence toxicology studies withRutherrin® to determine the maximum recommended human doseof the drug, when administered systemically into the human body,via intravenous injections. Due to the limitations of using laser light to activate Rutherrin® indeep oncological targets, Theralase’s research strongly suggeststhat Rutherrin® may be activated with radiation therapy, which isable to increase the ‘tumour’s damage zone’ and the effectivenessof the anti-cancer therapy beyond the reach of light in the body.

Finally something about actually making progress with IV Rutherrin and xray activation!! "Planning to commence" needs to be soon, very soon IMO.

But the idiot management has a history to call more than 3 years as "immediate future"